Skip to main content

Becton Dickinson Value Stock - Dividend - Research Selection

Becton dickinson

ISIN: US0758871091 , WKN: 857675

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women\'s health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


BD Earnings: What To Look For From BDX

2026-02-08
Medical technology company Becton, Dickinson and Company (NYSE:BDX) will be reporting results this Monday before the bell. Here’s what to expect.

Watts Water (WTS) Carrying a Favorable Sentiment After Becton Dickinson Deal

2026-02-06
Watts Water Technologies (NYSE:WTS) is one of the 15 best Industrial Machinery and Supplies stocks to buy according to Hedge Funds. On January 27, HSBC analyst Sidharth Sahoo initiated coverage of Watts Water (NYSE: WTS), assigning a Buy rating and a $460 price target. This results in a potential upside of nearly 51% from the […]

Can Sustained Product Demand Drive BDX Stock Before Q1 Earnings?

2026-02-05
BD rides on sustained product demand across Medical, Life Sciences and Interventional, but China market dynamics may pressure first-quarter fiscal 2026 results.

Countdown to Becton Dickinson (BDX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

2026-02-04
Get a deeper insight into the potential performance of Becton Dickinson (BDX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

A Look At Becton Dickinson (BDX) Valuation After Mixed Recent Share Price Performance

2026-02-04
What recent performance says about Becton Dickinson (BDX) Becton Dickinson (BDX) has drawn fresh attention after a period of mixed returns, with the share price up over the past month and past 3 months, but showing negative total returns over one, three and five years. See our latest analysis for Becton Dickinson. The recent 2.27% 1 day share price return and 17.07% 90 day share price return to about US$206.50 suggest short term momentum is improving, even though the 1 year total shareholder...

Citi bullish on Becton Dickinson after Life Sciences sale

2026-02-03
Investing.com -- Citi resumed coverage of Becton Dickinson with a Buy rating and a $233 price target, saying the company’s sale of its Life Sciences Bioprocessing unit reshapes it into a more focused medical technology business with clearer growth prospects.The sale, which is set to close on February 9, 2026, will leave BD as a pure-play MedTech company operating across four areas: Medical Essentials, Connected Care, Biopharma Systems and Interventional.Citi said these businesses address a rough

Staar Surgical (STAA) to Report Q4 Results: Wall Street Expects Earnings Growth

2026-02-03
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Piper Sandler Highlights Upcoming Segment Transition at Becton Dickinson (BDX)

2026-02-03
Becton, Dickinson and Company (NYSE:BDX) is included among the Dividend Growth Stocks: 25 Aristocrats. On January 28, Piper Sandler analyst Jason Bednar lifted Becton, Dickinson and Company (NYSE:BDX)’s price recommendation to $205 from $190. The analyst maintained a Neutral rating. The firm pointed to changes in how BD reports its business units starting in Q1 […]

Waters Corporation: Bigger, Better, But Fairly Priced

2026-02-03
Waters Corporation is pursuing a transformative merger to double revenue; regulatory lock-in supports high ROIC and EPS growth. Click to read more on WAT stock.

Becton, Dickinson and Company (BDX): A Bull Case Theory

2026-02-03
We came across a bullish thesis on Becton, Dickinson and Company on Value Don’t Lie’s Substack. In this article, we will summarize the bulls’ thesis on BDX. Becton, Dickinson and Company’s share was trading at $201.09 as of January 29th. BDX’s trailing and forward P/E were 34.55 and 13.44 respectively according to Yahoo Finance. Becton, Dickinson and Company develops, manufactures, […]